Tiziana Life Sciences

www.tizianalifesciences.com TICKER: TILS     EXCHANGE: AIM

Tiziana Life Sciences' research programme has identified a potential 'master regulator' for metastatic breast cancer (mBC). 'Bcl-3 inhibition' would be a novel strategy for treatment, complementary to conventional treatment for mBC, and raises hopes for better survival outcomes.

LATEST REPORTS

 
Clinical activities to signal inflection point
Published: Jan 25 2015

TILS has just announced an exclusive license with Nerviano Medical Sciences (NMS) for its Phase 2 anti-cancer drug candidate, milciclib. It helps block the rampant cell division associated with cancer growth. It already has approved Orphan drug status (US and EU) for treating malignant thymoma. TILS is aiming to start a Phase 2 study in liver cancer (H1 2015) and breast cancer. An early, but highly promising investment opportunity.
The expanding clinical portfolio should create value. We anticipate that moving milciclib through clinical development, separately to foralumab, should support, and hopefully extend, our current forecast valuation range for TILS of £40m-£60m. In tandem, we would also expect a fund raising, in due course, to support these potentially exciting clinical activities.
 
Foralumab license brings the clinic closer
Published: Jan 12 2015

Tiziana (TILS)  and Novimmune S.A., a company focused on the discovery and development of antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer, have announced that they have entered into an agreement under which Novimmune grants Tiziana an exclusive license for the clinical development and commercialisation of foralumab, a fully human antihuman CD3 receptor monoclonal antibody (CD3 mAb).
Tiziana will pay an upfront fee of $1.25 million for the license to Novimmune and will make further payments to Novimmune totalling $750,000 by February 2018. This moves TILS from preclinical to clinical development status, offering a low entry price, but opportunities in big markets. 
Tiziana's strategy is to build a clinical portfolio which should create value. We anticipate that moving foralumab into clinical development should support, and hopefully extend, our current forecast valuation range for TILS of £40m-£60m.
 
Tiziana Life Sciences Interim Results Webinar - October 2014
Published: Oct 19 2014

Phil Boyd, CFO of Tiziana Life Sciences plc, gives an excellent presentation on the science behind TILS progress in halting the spread of metastatic breast cancer.  He also discusses the opportunities for licensing this technology to other cancer treatments, the cash position for the business, and the possible options to realise value for shareholders in the future.  
 
Novel research focus on leading candidates
Published: Sep 30 2014

Tiziana Life Sciences (TILS) has identified a potential 'master regulator' for metastatic breast cancer (mBC). 'Bcl-3 inhibition' would be a novel strategy for treatment, complementary to conventional treatment for mBC, and raises hopes for better survival outcomes. 
Today's maiden interim results highlight successful fund raisings. TILS raised £2m in its April placing concurrent with the reverse acquisition of Alexander David Investments, and a further £0.73m (April) and £1.45m (June) via the issue of convertible loan notes. 
TILS' own strategy is a product out-licensing model or trade sale exit.Our forecast earnings model based on licensing deals over five advanced cancer indications supports a company valuation range of £40m-£60m.
 
Containing cancer's rampant spread
Published: Apr 24 2014

Tiziana Life Sciences started trading 24 April. In conjunction with a placing for £2m, this completed a £7.5m reverse takeover of Alexander David Investments plc (ADI) by Tiziana Pharma. 
Tiziana has a potentially unique and differentiated treatment approach to inhibit the spread of cancer (metastasis). This could improve survival times for advanced mBC cases and allow oncologists more time to profile and treat the primary tumour in earlier stages. About 90% of patients diagnosed with cancer die from such secondary cancer metastases.
Potential lead inhibitor molecules are currently being tested in a number of relevant in vivo preclinical mBC models, with an initial target for first-in-human trials by early-2017. Use in other cancer indications is a possibility.
The strategy is an out-licensing model or trade sale exit - on the basis of published research, the current encouraging progress and the high unmet need for anti-metastasis agents we believe that both scenarios are possible.
Our forecast earnings model based on licensing deals over five advanced cancer indications supports a company valuation range of £14m-£28m. 

ARCHIVE